Cargando…
Plasma Metabolic Disturbances in Parkinson’s Disease Patients
Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775245/ https://www.ncbi.nlm.nih.gov/pubmed/36551761 http://dx.doi.org/10.3390/biomedicines10123005 |
_version_ | 1784855596728582144 |
---|---|
author | Gątarek, Paulina Sekulska-Nalewajko, Joanna Bobrowska-Korczaka, Barbara Pawełczyk, Małgorzata Jastrzębski, Karol Głąbiński, Andrzej Kałużna-Czaplińska, Joanna |
author_facet | Gątarek, Paulina Sekulska-Nalewajko, Joanna Bobrowska-Korczaka, Barbara Pawełczyk, Małgorzata Jastrzębski, Karol Głąbiński, Andrzej Kałużna-Czaplińska, Joanna |
author_sort | Gątarek, Paulina |
collection | PubMed |
description | Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD. However, a growing body of scientific reports indicates that metabolic changes may precede and directly contribute to neurodegeneration. Identification and characterization of the abnormal metabolic pattern in patients’ plasma are therefore crucial for the search for potential PD biomarkers. The aims of the present study were (1) to identify metabolic alterations in plasma metabolome in subjects with PD as compared with the controls; (2) to find new potential markers, some correlations among them; (3) to identify metabolic pathways relevant to the pathophysiology of PD. Plasma samples from patients with PD (n = 25) and control group (n = 12) were collected and the gas chromatography-time-of-flight-mass spectrometry GC-TOFMS-based metabolomics approach was used to evaluate the metabolic changes based on the identified 14 metabolites with significantly altered levels using univariate and multivariate statistical analysis. The panel, including 6 metabolites (L-3-methoxytyrosine, aconitic acid, L-methionine, 13-docosenamide, hippuric acid, 9,12-octadecadienoic acid), was identified to discriminate PD from controls with the area under the curve (AUC) of 0.975, with an accuracy of 92%. We also used statistical criteria to identify the significantly altered level of metabolites. The metabolic pathways involved were associated with linoleic acid metabolism, mitochondrial electron transport chain, glycerolipid metabolism, and bile acid biosynthesis. These abnormal metabolic changes in the plasma of patients with PD were mainly related to the amino acid metabolism, TCA cycle metabolism, and mitochondrial function. |
format | Online Article Text |
id | pubmed-9775245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97752452022-12-23 Plasma Metabolic Disturbances in Parkinson’s Disease Patients Gątarek, Paulina Sekulska-Nalewajko, Joanna Bobrowska-Korczaka, Barbara Pawełczyk, Małgorzata Jastrzębski, Karol Głąbiński, Andrzej Kałużna-Czaplińska, Joanna Biomedicines Article Plasma from patients with Parkinson’s disease (PD) is a valuable source of information indicating altered metabolites associated with the risk or progression of the disease. Neurotoxicity of dopaminergic neurons, which is triggered by aggregation of α-synuclein, is the main pathogenic feature of PD. However, a growing body of scientific reports indicates that metabolic changes may precede and directly contribute to neurodegeneration. Identification and characterization of the abnormal metabolic pattern in patients’ plasma are therefore crucial for the search for potential PD biomarkers. The aims of the present study were (1) to identify metabolic alterations in plasma metabolome in subjects with PD as compared with the controls; (2) to find new potential markers, some correlations among them; (3) to identify metabolic pathways relevant to the pathophysiology of PD. Plasma samples from patients with PD (n = 25) and control group (n = 12) were collected and the gas chromatography-time-of-flight-mass spectrometry GC-TOFMS-based metabolomics approach was used to evaluate the metabolic changes based on the identified 14 metabolites with significantly altered levels using univariate and multivariate statistical analysis. The panel, including 6 metabolites (L-3-methoxytyrosine, aconitic acid, L-methionine, 13-docosenamide, hippuric acid, 9,12-octadecadienoic acid), was identified to discriminate PD from controls with the area under the curve (AUC) of 0.975, with an accuracy of 92%. We also used statistical criteria to identify the significantly altered level of metabolites. The metabolic pathways involved were associated with linoleic acid metabolism, mitochondrial electron transport chain, glycerolipid metabolism, and bile acid biosynthesis. These abnormal metabolic changes in the plasma of patients with PD were mainly related to the amino acid metabolism, TCA cycle metabolism, and mitochondrial function. MDPI 2022-11-22 /pmc/articles/PMC9775245/ /pubmed/36551761 http://dx.doi.org/10.3390/biomedicines10123005 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gątarek, Paulina Sekulska-Nalewajko, Joanna Bobrowska-Korczaka, Barbara Pawełczyk, Małgorzata Jastrzębski, Karol Głąbiński, Andrzej Kałużna-Czaplińska, Joanna Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title | Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title_full | Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title_fullStr | Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title_full_unstemmed | Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title_short | Plasma Metabolic Disturbances in Parkinson’s Disease Patients |
title_sort | plasma metabolic disturbances in parkinson’s disease patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775245/ https://www.ncbi.nlm.nih.gov/pubmed/36551761 http://dx.doi.org/10.3390/biomedicines10123005 |
work_keys_str_mv | AT gatarekpaulina plasmametabolicdisturbancesinparkinsonsdiseasepatients AT sekulskanalewajkojoanna plasmametabolicdisturbancesinparkinsonsdiseasepatients AT bobrowskakorczakabarbara plasmametabolicdisturbancesinparkinsonsdiseasepatients AT pawełczykmałgorzata plasmametabolicdisturbancesinparkinsonsdiseasepatients AT jastrzebskikarol plasmametabolicdisturbancesinparkinsonsdiseasepatients AT głabinskiandrzej plasmametabolicdisturbancesinparkinsonsdiseasepatients AT kałuznaczaplinskajoanna plasmametabolicdisturbancesinparkinsonsdiseasepatients |